Induction of immunogenic cell death by novel platinum-based anticancer agents

Abstract

Traditional platinum-based anticancer drugs, led by cisplatin, play an important role in chemotherapy. However, the development of platinum compounds is limited due to serious toxicity and side effects. In recent years, studies have showed that immunogenic cell death (ICD) may be one of the potential action mechanisms of classical platinum drugs, such as oxaliplatin. This strategy combining chemotherapy and immunotherapy can effectively utilize the body's immune system to help platinum compounds to fight against tumors, and the dose can be appropriately reduced to limit toxic side effects. The induction of ICD by platinum compounds has become a research hotspot and one of the future development directions of metal drugs. Here, the progress of platinum compounds were collected and comprehensively summarized, their capacity of ICD induction and mechanism of action are exposed, providing reference for the design and synthesis of new anticancer platinum ICD inducers.

Keywords: 163196301); 252–41709); 426756); 5702198); 9887053); Anticancer Cisplatin (PubChem CID; Carboplatin (PubChem CID; Immunogenic cell death; Oxaliplatin; Oxaliplatin (PubChem CID; Platinum derivatives; R,R-1,2 cyclohexanediamine-pyrophosphato-platinum(II) (PubChem CID; [1,3-diethyl-4,5-bis(4-fluorophenyl)− 2-imidazol][pyridine]-diiodoplatinum(II) (PubChem CID.